Emerging Trends of AI and ML in the Future of Pathology and Medicine

Shelly Garg
Amity University

Sakshi Gupta
Dron Acharya College of Engineering

Ashima Narang
Amity University

Abstract: This paper discusses emerging trends of AI and ML in the future of medical sciences. AI and ML tools play an important role in algorithms processing power to analyse data and produce better insights for healthcare systems. This paper also dwells with the pathology research, where they support automated image processing, drug development, clinical trials, biomarker discovery, and productive analytics. The use of ML operations to manage models in clinical settings, multimodal and multiagent AI to leverage a variety of data sources, accelerated translational research, and virtualized education for training and simulation are additional connected themes. This review paper explores the present use, future directions, and transformational potential of AI ML platforms in pathology and medicine. It covers their applications, advantages, difficulties, and future views.

Keywords: AI-ML, Pathology, Data Analysis

I. Introduction

In recent years, the exponential growth of data and significant advancements in computational technologies have propelled the widespread adoption of Machine Learning (ML) across the healthcare sector. The integration of ML into pathology and clinical medicine has opened new avenues for enhancing diagnostic precision, optimizing laboratory workflows, and elevating the overall quality of patient care. However, the effective development, deployment, and maintenance of these ML systems demand a suite of compatible tools and hardware, which can be difficult and inefficient to coordinate manually. To address this challenge, modern ML platforms have emerged, offering integrated frameworks that combine software, hardware, and streamlined processes to facilitate the scalable development and deployment of ML models for various healthcare applications. These platforms leverage advanced computational pipelines and sophisticated algorithms to automate and standardize each phase of the ML model lifecycle—including data acquisition and preprocessing, model training and validation, deployment, and ongoing performance monitoring. By utilizing such standardized platforms, healthcare institutions can significantly reduce complexity and improve the reliability and efficiency of machine learning implementation in clinical settings. Modern Machine Learning (ML) platforms are highly versatile and can be deployed across a range of applications, such as case management systems or digital pathology viewing software, with the added benefit of a well-documented build strategy and comprehensive performance evaluation. From an operational standpoint, an ML platform functions as a centralized ecosystem that facilitates collaboration among data scientists, engineers, analysts, and other key stakeholders—including developers, physicians, and regulatory specialists. These platforms integrate a suite of tools and services that streamline the entire ML lifecycle, encompassing data preparation, model development, valuation, deployment, integration, monitoring, and iterative feedback.Currently, Artificial Intelligence (AI) and ML platforms are increasingly used across various domains of healthcare, with a particularly transformative impact on medical imaging analysis and interpretation. These platforms enable the deployment of applications for (semi-)automated analysis of medical images—such as whole-slide images (WSIs), dermoscopy, ophthalmologic scans, X-rays, Computed Tomography (CT), and Magnetic Resonance Imaging (MRI)—to support the detection of abnormalities, disease diagnosis, and prediction of normal or benign conditions [1-5]. In pathology, AI-ML applications are being designed with advanced capabilities for image segmentation and quantitative analysis, assisting pathologists in the identification and assessment of tissue structures, cell types, and biomarkers. These tools promote greater precision, standardization, and operational efficiency [6-10]. Moreover, integrating AI-ML into clinical decision support systems enhances diagnostic accuracy and facilitates more effective treatment planning by analysing clinical data in real-time and generating evidence-based insights and alerts. AI-ML platforms are also advancing personalized medicine by enabling the analysis of patient-specific data—including genetic profiles, biomarkers, and disease phenotypes—to tailor treatment plans with greater precision. This data-driven approach holds significant promise for delivering more effective, targeted healthcare interventions. In parallel, the emergence of wearable devices and Internet of Things (IoT) sensors has enabled continuous monitoring of outpatient health indicators, such as daily activity metrics, outside of clinical settings[11-16].These platforms further integrate with Electronic Health Record (EHR) systems to enhance data interoperability, automate clinical documentation, and provide healthcare professionals with holistic, real-time patient insights at the point of care [17].

As AI-ML platforms become more deeply integrated into healthcare operations, a collaborative model involving data scientists and clinically literate healthcare providers is becoming increasingly essential. This partnership is expected to drive forward a synergistic approach to patient care—enhancing diagnostic accuracy, improving workflow efficiency.

II. Machine Learning Operations (ML-Ops)

In the industrial application of information technology (IT), mature practices are characterized by a comprehensive life cycle that includes software and system development, deployment, operational management, and eventual replacement. This integration of development and operations within an enterprise framework is widely known as **DevOps**. In the realm of artificial intelligence and machine learning, a comparable discipline has emerged, referred to as **Machine Learning Operations (ML-Ops)**. ML-Ops encompasses a suite of tools and best practices designed to manage the deployment and monitoring of machine learning models in production environments, such as routine clinical settings [18].Much like DevOps, ML-Ops facilitates seamless collaboration among diverse stakeholders, including data scientists, IT professionals, subject matter experts, and operational leadership. In the healthcare context, ML-Ops serves a critical function by fostering interdisciplinary cooperation between physicians, data scientists, cybersecurity specialists, and administrators, thereby aligning technical ML decision-making with patient-centered clinical outcomes [19]. Modern ML platforms are central to enabling ML-Ops, providing an integrated environment that supports coordination, version control, performance monitoring, and feedback mechanisms essential for reliable clinical deployment.

An essential tenet of ML-Ops is the **recognition of human oversight throughout the ML model life cycle**. This is operationalized through *human-in-the-loop* processes, which ensure that human judgment remains involved in crucial stages such as data annotation, model training, validation, output interpretation, and ethical assessment of AI recommendations. While ML models can assist in various aspects of diagnostics and decision support, the deployment of these systems in clinical laboratories must retain a high degree of human validation. Specifically, pathologists and other medical professionals must continue to act as final arbiters in interpreting ML-generated outputs to ensure the accuracy and precision of patient test results.

Although the future may see the emergence of more autonomous AI systems in healthcare, their current implementation remains limited due to regulatory, ethical, and operational considerations [20]. ML-Ops thus bridges the gap between technological innovation and clinical responsibility, supporting the trustworthy and effective use of AI/ML systems in medical practice.

III. Multimodal Artificial Intelligence in Healthcare

Multimodal artificial intelligence (AI) refers to the integration of diverse data types—such as medical imaging and magnetic resonance imaging genomic information (e.g., DNA and RNA sequencing), and clinical data (e.g., patient demographics, laboratory test results, and medical histories)—within a unified AI-ML system to enhance decision-making in healthcare [21]. By combining multiple sources of patient data, multimodal AI enables a more comprehensive and context-aware analysis, supporting personalized and holistic patient management strategies. Compared to unimodal models that rely on a single data source, multimodal AI offers several significant advantages in pathology and laboratory medicine. These include improved diagnostic accuracy, greater robustness in handling context-rich clinical tasks, and more efficient use of data. For instance, imaging abnormalities can be interpreted alongside relevant genomic markers that may indicate disease susceptibility or progression, allowing for deeper clinical insight and more actionable diagnostic output.

In current clinical practice, most AI implementations still rely on unimodal approaches, which—while helpful—may not provide a full clinical picture. Multimodal AI systems, by contrast, synthesize different dimensions of patient health data to uncover subtle patterns and correlations that may go unnoticed with single-modality analysis. For example, integrating histopathological image analysis with genomic sequencing data allows AI systems to detect molecular mechanisms underlying disease progression, thus enabling more precise diagnostics and prognostication. Chen et al. [22] exemplify the power of this approach with a multimodal deep learning model that combines pathology WSI analysis with molecular profiling across 14 cancer types. Their model not only predicted patient outcomes effectively but also identified prognostic features associated with favorable and unfavorable clinical trajectories. Such integration reduces diagnostic errors, minimizes inter-observer variability, and enhances the reproducibility and reliability of clinical interpretations. In addition to improving diagnostic accuracy, multimodal AI significantly increases diagnostic efficiency by automating the integration and analysis of heterogeneous data sources. This rapid processing is particularly beneficial in time-sensitive clinical scenarios, such as intraoperative consultations, cancer diagnostics, or infectious disease evaluations [23, 24].

Furthermore, multimodal AI plays a pivotal role in advancing **precision medicine**. By incorporating genomic, imaging, and clinical parameters, AI models can stratify patients based on risk, prognosis, and predicted therapeutic response. This enables clinicians to tailor treatment strategies to the individual, reduce potential adverse effects, and improve clinical outcomes. AI-powered decision support systems can even recommend personalized therapies or clinical trial opportunities based on a patient's genetic profile, disease stage, histomorphology, and demographics.

Ultimately, the use of multimodal AI facilitates more precise disease modeling, enhances treatment prediction accuracy, and supports higher levels of patient satisfaction—all while optimizing healthcare resource allocation and improving overall outcomes [21].

IV. Artificial General Intelligence in Healthcare

Artificial General Intelligence (AGI) refers to a conceptual form of AI that exhibits the ability to understand, learn, and apply knowledge across a wide array of tasks at a level comparable to that of a human being [25]. As of August 2024, AGI has not yet been realized. However, rapid advancements in artificial intelligence research have demonstrated significant progress that may pave the way toward this goal. Unlike narrow AI—also known as weak AI—which dominates current medical applications and is designed for specific, predefined tasks (e.g., tumor classification or image segmentation), AGI would possess the capacity to perform a wide range of intellectual tasks without being constrained to a single domain.

Conceptually, AGI holds transformative potential for the field of medicine. An AGI-enabled system could theoretically analyze and synthesize vast, heterogeneous health data—including medical histories, treatment records, genomic profiles, data from wearable devices, lifestyle metrics, pathology reports, and laboratory results. From this, AGI could assess disease risk, propose preventative interventions, and support personalized treatment decisions. Furthermore, AGI could assist with complex surgical planning and execution, monitor patient health in real time, and offer adaptive health advice aligned with individual patient profiles. In the realm of biomedical research, AGI could dramatically accelerate drug discovery by modeling chemical interactions, predicting therapeutic efficacy, and assessing toxicity—all with an efficiency far beyond current capabilities. This could significantly reduce the time and cost associated with bringing novel therapeutics to clinical use.

Despite these prospects, AGI remains a theoretical construct. Present-day healthcare AI solutions remain rooted in narrow AI paradigms, optimized for tasks like image analysis, pattern recognition, and clinical outcome prediction. Nonetheless, there is growing global interest in developing AGI frameworks that can integrate multimodal health data, draw complex inferences, and support high-level clinical decision-making.

The pursuit of AGI is not without formidable challenges. It requires extensive volumes of high-quality, diverse datasets; advanced models capable of simulating human cognition; and major breakthroughs in subfields such as Machine Learning (ML), Natural Language Processing (NLP), and cognitive modeling. Moreover, the development of AGI raises profound ethical, regulatory, and societal concerns. These include issues of data privacy and security, algorithmic bias, job displacement, decision accountability, and equitable access to AGI-driven technologies.

In anticipation of these challenges, it is imperative that the development of AGI—particularly for healthcare applications—be guided by transparent, inclusive, and ethically grounded frameworks. Engaging a broad spectrum of stakeholders—including patients, healthcare professionals, ethicists, policymakers, and civil society organizations—will be essential in shaping responsible governance, regulatory oversight, and public trust in AGI.

Ultimately, while AGI is still in its nascent conceptual stage, its potential to revolutionize healthcare delivery, enhance clinical outcomes, and solve persistent system-wide challenges makes it one of the most promising—and consequential—frontiers in artificial intelligence research.

V. Artificial Intelligence in Medical Research

Artificial Intelligence (AI) and Machine Learning (ML) platforms are used to fundamentally reshape the landscape of scientific research in healthcare. Among their most transformative capabilities is the ability to rapidly analyze and extract insights from massive, heterogeneous datasets, uncovering complex patterns and relationships that often surpass the limits of traditional analytical methods. This is especially impactful in high-data-volume fields such as genomics, medical imaging, and population health.

In **genomics**, AI-ML algorithms can analyze genetic sequencing data to identify potential biomarkers for disease susceptibility, prognosis, and therapeutic targeting—advancing the goals of precision medicine. Beyond genomics, AI-ML has enabled the discovery of novel biomarkers through **radiomics** and **pathomics**, and is now extending into **transcriptomics** and **epigenomics** [26-28].This broadened molecular insight allows researchers to better understand disease mechanisms and epidemiological patterns [29-30].

The emergence of **digital biobanks** has further expanded the potential of AI-ML in research. These repositories store vast volumes of biological, genomic, and clinical data. AI-ML enhances their utility by improving data integration, enabling advanced querying, and uncovering subtle trends within digital datasets. In recent studies, AI has also been leveraged to generate **synthetic data** to support research efforts while maintaining data privacy, thereby improving **data accessibility**, reproducibility, and research productivity [31-34]. AI is also transforming the **clinical trial ecosystem**. By analyzing biobank data and electronic health records, AI-ML platforms can optimize trial design, identify suitable participants based on complex inclusion criteria, and predict trial feasibility. They support **adaptive trial designs**, which allow real-time adjustments based on interim results—thereby improving trial efficiency and reducing costs. The use of **digital twins**—dynamic AI-driven simulations of real-world patients or systems—has introduced new possibilities for modeling disease progression and evaluating treatment outcomes before human testing. For example, Peshkova et al. [35] demonstrated the use of pathology-based digital twins to simulate colorectal carcinoma for diagnostic tool development.

In **epidemiology**, AI-ML tools are increasingly used to model disease outbreaks and assess public health risks. These systems have already proven their value during the COVID-19 pandemic by forecasting transmission dynamics and supporting real-time response strategies [36-37].

In the realm of **drug discovery**, AI is revolutionizing the research pipeline. By analyzing diverse biological data, AI algorithms can identify novel drug targets, evaluate compound efficacy, and even **repurpose existing drugs** for new therapeutic applications. Predictive modeling allows researchers to simulate drug interactions with biological systems to forecast efficacy and side effects before advancing to clinical trials. AI is also accelerating **de novo drug design** and **vaccine development**, enabling the rapid identification of promising candidates and optimization of development strategies [38-41].

Personalized medicine stands to benefit significantly from AI-ML platforms. By analyzing genomic, clinical, and lifestyle data, AI enables stratification of patients into subgroups more likely to respond to specific therapies, enhancing both efficacy and safety. AI is further driving innovation in **spatial biology**, **tumor microenvironment (TME) analysis**, and **multiplexed molecular imaging**. The ability to interpret spatial and multiomic data provides unprecedented insights into how cellular and molecular components interact within tissues, contributing to more accurate prognostics and therapeutic decision-making. Fu et al. [42], for instance, demonstrated the use of AI in enhancing spatial resolution to better understand tumor biology and predict clinical outcomes.

Finally, **large language models (LLMs)** such as those based on transformer architectures are emerging as invaluable tools in biomedical research. These models can automate literature searches, synthesize key findings, and assist in knowledge extraction from vast scientific corpora. By helping researchers identify knowledge gaps and summarize complex topics, LLMs are accelerating the pace of innovation and supporting evidence-based research across disciplines.In summary, AI-ML platforms are becoming integral to the future of medical research. Their applications—from genomic analysis and drug discovery to digital twin modeling and literature synthesis—will continue to evolve, driving significant advancements in our understanding, diagnosis, and treatment of complex medical conditions. These technologies hold the potential to catalyze a new era of precision health and translational science.

VI.Conclusion

The integration of AI and ML in healthcare is transforming diagnostics, clinical workflows, and personalized medicine. Key advancements like ML-Ops, multimodal AI, and AGI are reshaping research and decision-making. Success depends on cross-disciplinary collaboration and sustained investment. AI enhances diagnosis, efficiency, and patient outcomes while also revolutionizing research and medical education. To unlock its full potential, ethical and regulatory challenges must be addressed, ensuring responsible and equitable adoption of AI in global healthcare systems.

References

1. Gore JC. Artificial intelligence in medical imaging. Magn Reson Imaging. 2020;68:A1eA4.
2. Barrag_an-Montero A, Javaid U, Vald_es G, et al. Artificial intelligence and machine learning for medical imaging: a technology review. Phys Med. 2021; 83:242e256.
3. Campanella G, Hanna MG, Geneslaw L, et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. Nat Med. 2019; 25(8):1301e1309. Rajpara SM, Botello AP, Townend J, Ormerod AD. Systematic review of dermoscopy and digital dermoscopy/ artificial intelligence for the diagnosis of melanoma. Br J Dermatol. 2009;161(3):591e604.
4. Ting DSW, Pasquale LR, Peng L, et al. Artificial intelligence and deep learning in ophthalmology. Br J Ophthalmol. 2019;103(2):167e175.
5. Stålhammar G, Fuentes Martinez N, Lippert M, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016;29(4):318e329.
6. Cornish TC. Clinical application of image analysis in pathology. Adv Anat Pathol. 2020;27(4):227e235. Holten-Rossing H, Talman MM, Jylling AMB, Laenkholm AV, Kristensson M, Vainer B. Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer. Histopathology. 2017;71(6):866e873.
7. Volynskaya Z, Mete O, Pakbaz S, Al-Ghamdi D, Asa SL. Ki67 quantitative interpretation: insights using image analysis. J Pathol Inform. 2019;10:8.
8. Gil J, Wu HS. Applications of image analysis to anatomic pathology: realities and promises. Cancer Invest. 2003;21(6):950e959.
9. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381(20): 1909e1917.
10. Nahavandi D, Alizadehsani R, Khosravi A, Acharya UR. Application of artificial intelligence in wearable devices: opportunities and challenges. Comput Methods Programs Biomed. 2022;213:106541.
11. Lubitz SA, Faranesh AZ, Selvaggi C, et al. Detection of atrial fibrillation in a large population using wearable devices: the Fitbit Heart Study. Circulation. 2022;146(19):1415e1424.
12. Hijazi H, Abu Talib M, Hasasneh A, Bou Nassif A, Ahmed N, Nasir Q. Wearable devices, smartphones, and interpretable artificial intelligence in combating COVID-19. Sensors (Basel). 2021;21(24):8424. M€akynen M, Ng GA, Li X, Schlindwein FS. Wearable devices combined with artificial intelligence-a future technology for atrial fibrillation detection? Sensors (Basel). 2022;22(22):8588.
13. Wang WH, Hsu WS. Integrating artificial intelligence and wearable IoT system in long-term care environments. Sensors (Basel). 2023;23(13):5913.
14. Hossain E, Rana R, Higgins N, et al. Natural language processing in electronic health records in relation to healthcare decision-making: a systematic review. Comput Biol Med. 2023;155:106649.
15. Huyen C. Designing Machine Learning Systems. O'Reilly Media Inc; 2022. Accessed June 23, 2024.
16. Sculley D, Holt G, Golovin D, et al. Hidden technical debt in machine learning systems. In: Proceedings of the 28th International Conference on Neural Information Processing Systems-Volume 2. MIT Press; 2015:2503e2511. NIPS’15.
17. Abramoff MD, Whitestone N, Patnaik JL, et al. Autonomous artificial intelligence increases real-world specialist clinic productivity in a clusterrandomized trial. NPJ Digit Med. 2023;6(1):184.
18. Ngiam KY, Khor IW. Big data and machine learning algorithms for health-care delivery. Lancet Oncol. 2019;20(5):e262ee273.
19. Chen RJ, Lu MY, Williamson DFK, et al. Pan-cancer integrative histologygenomic analysis via multimodal deep learning. Cancer Cell. 2022;40(8):865e878.e6.
20. Lipkova J, Chen RJ, Chen B, et al. Artificial intelligence for multimodal data integration in oncology. Cancer Cell. 2022;40(10):1095e1110.
21. Xia Y, Ji Z, Krylov A, Chang H, Cai W. Machine learning in multimodal medical imaging. Biomed Res Int. 2017;2017:1278329.
22. Goertzel B, Pennachin C, eds. Artificial General Intelligence. Springer; 2007.
23. Prelaj A, Miskovic V, Zanitti M, et al. Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review. Ann Oncol. 2024; 35(1):29e65. Mikdadi D, O’Connell KA, Meacham PJ, et al. Applications of artificial intelligence (AI) in ovarian cancer, pancreatic cancer, and image biomarker discovery. Cancer Biomark. 2022;33(2):173e184.
24. Çalıs¸ kan M, Tazaki K. AI/ML advances in non-small cell lung cancer biomarker discovery. Front Oncol. 2023;13:1260374.
25. Rasmusson A, Zilenaite D, Nestarenkaite A, et al. Immunogradient indicators for antitumor

response assessment by automated tumor-stroma interface zone detection. Am J Pathol. 2020;190(6):1309e1322.

26. Chi J, Shu J, Li M, et al. Artificial intelligence in metabolomics: a current review. Trends Analyt Chem. 2024;178:117852. https://doi.org/10.1016/j.trac.2024.117852
27. Bonizzi G, Zattoni L, Fusco N. Biobanking in the digital pathology era. Oncol Res. 2022;29(4):229e233.
28. Brancato V, Esposito G, Coppola L, et al. Standardizing digital biobanks:integrating imaging, genomic, and clinical data for precision medicine. J Transl Med. 2024;22(1):136.
29. Frascarelli C, Bonizzi G, Musico CR, et al. Revolutionizing cancer research: the impact of artificial intelligence in digital biobanking. J Pers Med. 2023;13(9):1390.
30. Pantanowitz J, Manko CD, Pantanowitz L, Rashidi HH. Synthetic data and its utility in pathology and laboratory medicine. Lab Invest. 2024;104(8):102095. Peshkova M, Yumasheva V, Rudenko E, Kretova N, Timashev P, Demura T. Digital twin concept: healthcare, education, research. J Pathol Inform. 2023;14:100313.
31. Ankolekar A, Eppings L, Bottari F, et al. Using artificial intelligence and predictive modelling to enable learning healthcare systems (LHS) for
38. of tumour microenvironment organisation to predict prognosis and therapeutic response. J Pathol. 2023;260(5):578e591.

pandemic preparedness. Comput Struct Biotechnol J. 2024;24:412e419.

32. Demirbaga U, Kaur N, Aujla GS. Uncovering hidden and complex relations of pandemic dynamics using an AI driven system. Sci Rep. 2024;14(1):15433.
33. Gholap AD, Uddin MJ, Faiyazuddin M, Omri A, Gowri S, Khalid M. Advances in artificial intelligence for drug delivery and development: a comprehensive review. Comput Biol Med. 2024;178:108702.
34. Jimeno A, Moore KN, Gordon M, et al. A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors. Invest New Drugs. 2019;37(3): 461e472.
35. Visan AI, Negut I. Integrating artificial intelligence for drug discovery in the context of revolutionizing drug delivery. Life (Basel). 2024;14(2):233.
36. Singh S, Kumar R, Payra S, Singh SK. Artificial intelligence and machine learning in pharmacological research: bridging the gap between data and drug discovery. Cureus. 2023;15(8):e44359.
37. Fu X, Sahai E, Wilkins A. Application of digital pathology-based advanced analytics